Navigation Links
NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
Date:12/14/2007

rovide 13 and 26-week efficacy results and supportive safety data for the regulatory filing of naproxcinod, in addition to blood pressure data to aid its market differentiation. The completion of patient enrollment in the 303 study is now a top priority and together with the contract research organization for this trial, Covance Inc., we have taken the step of opening additional clinical centers in Europe to accelerate the recruitment in this study."

302 study design

The 302 study for naproxcinod was initiated in April, 2007 and is being conducted by Premier Research Group plc. This study is a 53-week, randomized, double-blind, efficacy and safety trial in which 1020 patients with osteoarthritis of the knee have been enrolled at 150 clinical sites throughout the United States. Patients have been randomized to one of the following treatment groups: naproxcinod 375 mg bid (52 weeks), naproxcinod 750 mg bid (52 weeks), naproxen 500 mg bid (52 weeks) and placebo bid during the first 13 weeks. After 13 weeks, the placebo treated patients are being randomized to either naproxcinod 375 mg bid or naproxcinod 750 mg bid for the remainder of the trial (39 weeks). Patients have primary osteoarthritis of the knee of at least 3 months duration. The trial has recruited both hypertensive and non-hypertensive patients, although patients with uncontrolled hypertension have been excluded.

The two doses of naproxcinod (750 mg and 375 mg bid) will be compared to placebo on three co-primary efficacy endpoints, based on the mean change between baseline and week-13 in the following scores: the WOMAC(TM) pain subscale, the WOMAC(TM) function subscale and subject's overall rating of disease status. These are the standard endpoints used to demonstrate the efficacy of drugs for treating the signs and symptoms of osteoarthritis and are the same as those used in the other two pivotal phase 3 studies for naproxcinod. A secondary endpoint of the trial is to compare the effica
'/>"/>

SOURCE NicOx S.A.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
2. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
3. NicOx Naproxcinod ABPM Data Presented at American Heart Association
4. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology
5. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
11. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 1, 2014 Sophia Genetics, ... domaine de l,analyse des données issues du SNG ... de diagnostic in vitro (IVD) du gène CFTR ... la mucoviscidose dans un seul essai SGN. La ... les types de variantes par l,intermédiaire d,un seul ...
(Date:9/30/2014)... -- Hologic, Inc. (NASDAQ: HOLX ), today announced ... Executive Officer, will preside over the NASDAQ Stock Market ... of Breast Cancer Awareness Month. In his remarks, Mr. ... important benefits of Hologic,s 3D Mammography technology, the only ... to traditional mammography. This is the ninth ...
(Date:9/30/2014)... , Sept. 30, 2014 Arbor Pharmaceuticals, ... Summary Global Markets Direct,s, ,Arbor Pharmaceuticals, LLC. ... overview of the Arbor Pharmaceuticals, LLC.,s pharmaceutical research ... information on the current therapeutic developmental pipeline of ... various stages, therapeutics assessment by drug target, mechanism ...
Breaking Medicine Technology:Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 2Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 3Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3
... , , VENLO, Netherlands , Feb. 2 QIAGEN N.V. ... financial results call. The Webcast will take place at 9:30 a.m. EST on ... President and Chief Executive Officer, and Roland Sackers, Chief Financial Officer. , ... QIAGEN,s fourth quarter and year-end 2009 financial , ...
... , JERUSALEM , Feb. ... ) announced today the availability of new resources to support ... to deliver Teva’s TEV-TROPIN® [somatropin (rDNA origin) for injection] brand ... due to inadequate secretion of normal endogenous growth hormone. The ...
Cached Medicine Technology:Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Fourth Quarter and Year-End 2009 Financial Results Call Set for February 9 2Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Fourth Quarter and Year-End 2009 Financial Results Call Set for February 9 3Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 2Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 3Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 4Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 5Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 6
(Date:10/1/2014)... Angeles, CA (PRWEB) October 01, 2014 ... power score of 3.1 out of 5, which ... users include food and beverage manufacturers, food service ... As a result of these users' diversity, demand ... As such, rising industrial production, consumer spending and ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 To help raise ... center , Cutler Integrative Medicine, is detailing several tips for ... , According to Dr. Cutler, women should start each ... time for yourself that will help ‘center’ yourself for the ... stress,” he says. , Other health and fitness tips ...
(Date:10/1/2014)... CO (PRWEB) October 01, 2014 Nearly ... after a Pueblo County District Court jury awarded him ... cancer at 61 years old. Casper had been ... , According to the Court Documents (District ... treated for BPH, a benign non-cancerous condition of his ...
(Date:9/30/2014)... be proactive about potential disease outbreaks like Ebola and ... an Editorial in the October issue of Australian ... Cheng from Monash University and Heath Kelly from the ... crises. , "Australia would do well to heed the ... co-ordinating a consistent and outward looking response," the authors ...
(Date:9/30/2014)... (HealthDay News) -- There,s no genetic evidence that high ... a new study says. Some previous research had ... people against type 2 diabetes, raising the possibility of ... sugar disease. In this study, British researchers investigated ... focusing on genes that control blood levels of vitamin ...
Breaking Medicine News(10 mins):Health News:Industrial Freezers Procurement Category Market Research Report Now Available from IBISWorld 2Health News:Industrial Freezers Procurement Category Market Research Report Now Available from IBISWorld 3Health News:Industrial Freezers Procurement Category Market Research Report Now Available from IBISWorld 4Health News:In Recognition of National Women’s Health and Fitness Day, Cutler Integrative Medicine Details Tips for Living a Healthier and Happier Life 2Health News:Law Offices of D.R. Jones Client Wins 4.7 Million Dollar Verdict, Insurance Company Files Motion for a New Trial 2Health News:Law Offices of D.R. Jones Client Wins 4.7 Million Dollar Verdict, Insurance Company Files Motion for a New Trial 3Health News:Gene Study Finds No Proof Vitamin D Guards Against Type 2 Diabetes 2
... -- Racism is similar to trauma in how it ... United States, a new analysis finds. An examination ... black adults concluded that there are common responses to ... is expressed as physical pain), interpersonal sensitivity and anxiety. ...
... Nov. 24 (HealthDay News) -- Black Friday, the kickoff to ... as it is about getting good deals, according to a ... Friday adventure phenomenon, the more fun you,re likely to add ... Wake Forest University, said in a university news release. ...
... -- A 36-year-old husband and father of two children with ... world,s first artificial trachea made with stem cells. ... described the transplant surgery, which was performed in June ... the transplant, the authors of the report explained, the man ...
... By Jenifer Goodwin HealthDay Reporter , WEDNESDAY, ... Americans are hospitalized for adverse drug reactions yearly, and ... a new study finds. The four types of ... -- account for two-thirds of those drug-related emergency hospitalizations. ...
... that treats Type-2 diabetes has been shown to prevent ... the growth of breast cancer cells, according to a ... The research, led by pediatrics professor James Trosko ... biological evidence for previously reported epidemiological surveys that long-term ...
... , WEDNESDAY, Nov. 23 (HealthDay News) -- Preschoolers who ... are often prescribed inhaled steroid medication, and new research ... as-needed basis instead of every day. Respiratory ... and the treatment for some of these kids -- ...
Cached Medicine News:Health News:1st Artificial Windpipe Made With Stem Cells Seems Successful 2Health News:Four Common Meds Send Thousands of Seniors to Hospital: CDC 2Health News:Four Common Meds Send Thousands of Seniors to Hospital: CDC 3Health News:Diabetes drug shows promise in reducing risk of cancer 2Health News:Intermittent Steroid Use Called OK for Wheezing Preschoolers 2Health News:Intermittent Steroid Use Called OK for Wheezing Preschoolers 3
... The National Laboratory Training Network (NLTN) ... Association of Public Health Laboratories (APHL) and ... (CDC). NLTN provides cost-effective training in a ... resources, including a FREE Lending Library. Log ...
... The AAFP-PT Laboratory Proficiency Testing and ... programs are designed to assist POLs, clinics ... are designed to assure accuracy of patient ... regulatory requirements. Participation provides the opportunity to ...
An indirect immunofluorescence (IFA) antibody test for the detection and semiquantitation of anti-glomerular basement membrane (GBM) antibodies in human serum. Slide Detail: 6-well Monkey Kidney Subs...
An enzyme linked immunosorbant assay (ELISA) for the detection and quantitation of Rheumatoid Factor (RF) of IgM isotype in human serum....
Medicine Products: